[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644685":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":53,"collaborators":26,"id":55,"slug":26,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":26,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":26,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":26,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Zhejiang Wenda Pharma Technology LTD.","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1:WD-890","EXPERIMENTAL","Drug:WD-890\n\nWD-890 tablet will be administered orally.",[13],"Drug: Drug:WD-890",{"label":15,"type":16,"description":17,"interventionNames":18},"Group 2: Placebo","PLACEBO_COMPARATOR","Drug: Placebo\n\nPlacebo tablet will be administered orally.",[19],"Drug: Drug: placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Drug:WD-890","WD-890 tablet will be administered orally.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Drug: placebo","Placebo tablet will be administered orally.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Lu Qianjin","CONTACT","+8613787097676","qianlu5860@gmail.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Hospital of Dermatology, Chinese Academy of Medical Sciences","RECRUITING","Nanjing","Jiangsu","210042","China",{"type":46,"coordinates":47},"Point",[48,49],118.77778,32.06167,{"lat":49,"lon":48},[52],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"type":54,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100644685",false,"NCT07672561","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\n* Male or female participant aged 18 to 75 years(inclusive)at the time of informed consent.\n* Diagnosis of plaque psoriasis for at least 6 months prior to the screening visit.\n* Body surface area (BSA) ≥10%, Psoriasis Area and Severity Index (PASI) score ≥12 and static Physician's Global Assessment (sPGA) ≥3 at screening visit and randomization\n\nExclusion Criteria:\n\n* Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, inverse, pustular,or drug induced psoriasis.)\n* Has uncontrolled arterial hypertension characterized by a systolic blood pressure (BP) ≥160 mm Hg or diastolic BP ≥100 mm Hg Note: Determined by 2 consecutive elevated readings. If an initial BP reading exceeds this limit, the BP may be repeated once after the subject has rested sitting for ≥10 minutes. If the repeat value is less than the criterion limits, the second value may be accepted\n* Class III or IV congestive heart failure by New York Heart Association Criteria",true,"ALL","18 Years","75 Years",{"count":65,"type":66},375,"ESTIMATED","INTERVENTIONAL",[69],"PHASE3","The purpose of the study is to evaluate the experimental medication WD-890 compared to placebo in participants with moderate-to-severe plaque psoriasis.",[72],"Moderate to Severe Plaque Psoriasis","2026-06-26",{"date":75,"type":76},"2026-06-29","ACTUAL",{"date":78,"type":76},"2026-03-18",{"date":80,"type":66},"2027-07-30",{"name":5,"class":6},1]